Transatlantic deal could increase EU pharma exports by $10 billion, report says

25 May 2016

The Transatlantic Trade and Investment Partnership (TTIP) could increase the annual value of European Union (EU) pharma exports by 9 billion Euros ($10.03 billion) by slashing trade barriers, a study suggests.

Up to 19,000 jobs in pharma and 60,000 more in related industries could also be created across the EU, the report by consultants Copenhagen Economics predicts.

The Transatlantic Trade and Investment Partnership Agreement (TTIP) is currently being negotiated between the EU and the USA, and EFPIA, the association representing European pharma, asked Copenhagen Economics to assess its potential impact.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK